Promoter NTK Files Appeal in Tokyo High Court Against Tokyo District Court Judgment

Promoter shareholder Northern TK Venture (IHH arm) has shared an appeal with the Tokyo High Court on 24 Sep 2026 against the Tokyo District Court judgment of 10 Sep 2026 in its claim against Daiichi Sankyo.

Fri 25 Sep 2026

Appeal Update Date

24 Sep 2026

Original Court Judgment Date

10 Sep 2026

Planned Stake Increase

51% over 3-5 years

Capacity Expansion Target

approximately 10,000 beds by 2031

What was shared

Fortis Healthcare has disclosed, under Regulation 30, an announcement made by IHH Healthcare Berhad on 24 September 2026 on Bursa Malaysia and SGX.

• Northern TK Venture Pte Ltd (NTK), the promoter shareholder of Fortis and an indirect wholly owned subsidiary of IHH, has shared a petition for appeal with the Tokyo High Court.
• The appeal is against the judgment issued by the Tokyo District Court dated 10 September 2026.
• NTK says it assessed the judgment and concluded it warrants appellate review by a higher court.

Background given

IHH's position is that it suffered losses arising from delays in obtaining the mandatory tender offer approvals required for its acquisition of Fortis Healthcare. Those delays arose in the context of a dispute between Daiichi Sankyo and certain judgment debtors, to which IHH states it was not a party. IHH states the 2018 acquisition went through a transparent, regulated process with all necessary corporate, shareholder and regulatory approvals, including CCI and SEBI takeover regulations.

Stated plans for India

• IHH plans to increase its stake in Fortis to 51% over the next three to five years.
• Further integration of the Fortis and Gleneagles platforms.
• Expansion of capacity to approximately 10,000 beds by 2031.

Context on IHH

IHH operates across 10 countries with a 76,000-strong team and 190 healthcare facilities, including 89 hospitals.

What it means for investors

This is a litigation involving the promoter shareholder NTK and Daiichi Sankyo before Japanese courts; the matter now moves to the appellate stage. The company has said it will inform the exchanges of any material developments.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.